medigraphic.com
ISSN 2448-8909 (Print)

2022, Number 3

<< Back Next >>

Med Crit 2022; 36 (3)

Difference in D-dimer levels in the presence of severe hypoxemia in patients with SARS-CoV-2 pneumonia admitted to therapy intensive

Ojeda SGL, Bravo SE, Ramírez MAH, López AL, Carmona CH

Language: Spanish
References: 24
Page: 161-167
PDF size: 256.56 Kb.


ABSTRACT

Introduction: SARS-CoV-2 was unknown until the outbreak in Wuhan, China in December 2019, the ultra-structural characteristics of this virus with predisposition to receptors expressed in type II pneumocytes (CD209L and ECA2), results in diffuse alveolar damage and a third of the patients with SARS-CoV-2 meet criteria for SIRA with severe hypoxemia. After the severe course of the disease and high mortality, the association of DD with severe cases was reported in studies and attributed to the prothrombotic state of the disease, directly contributing to prolonged mechanical ventilation and death. Main objective: To determine the different levels of DD in the presence of severe hypoxemia in patients with SARS-CoV-2 pneumonia admitted to intensive care. Material and methods: Cross-sectional retrospective single-center study, records of patients older than 18 years who were admitted to the intensive care unit with a diagnosis of SARS-CoV-2 pneumonia were reviewed; DD values on admission, on the seventh day and the PaO2/FiO2 ratio of arterial blood gases were considered. We defined severe hypoxemia PaO2/FiO2 less than 150 mmHg and after the Mann-Whitney U test, DD levels, ROC curve and AUC were evaluated for the DD cohort point and the association with oxygen supply therapy and its outcome with OR and HF 95%. Results: Records of 82 patients were studied, 81.7% presented severe hypoxemia on admission, and 74.4% on the seventh day; A median DD of 1,410 ng/mL was reported with severe hypoxemia and 2,238 ng/mL on the seventh day (p = 0.001). ROC curve found DD 1,500 ng/mL as a cohort point associated with severe hypoxemia (AUC: 0.808, 95% CI 0.706-0.910). On prognostic scales I report a higher score, APACHE II (24 pts, p = 0.036), SOFA (12 pts, p = 0.012), and SAPS II (67 pts, p ≤ 0.0001); as well as in deaths (81.6%, p ≤ 0.0001, OR 16.50 95% CI 5.472-49.80). Conclusion: DD greater than and/or equal to 1,500 ng/mL is associated with severe hypoxemia and higher mortality on the seventh day of stay in the ICU, indicating that DD is a potential early and useful marker to guide the therapy and evaluate the prognosis of the patient.


REFERENCES

  1. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 28 January 2020. Available in: https://apps.who.int/iris/handle/10665/330893

  2. Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci USA. 2004;101(44):15748-15753. doi: 10.1073/pnas.0403812101.

  3. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial r ole of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875-879. doi: 10.1038/nm1267.

  4. World Health Organization. Novel Coronavirus(2019-nCoV): situation report, 1. 2020. Available in: https://apps.who.int/iris/handle/10665/330760

  5. World Health Organization. 2020. Novel Coronavirus(2019-nCoV): situation report, 10. 2020. Available in: https://apps.who.int/iris/handle/10665/330775

  6. World Health Organization. 2020. Coronavirus disease 2019 (COVID-19): situation report, 38. 2020. Available in: https://apps.who.int/iris/handle/10665/331226

  7. World Health Organization. 2020. Coronavirus disease 2019 (COVID-19): situation report, 40. 2020. Available in: https://apps.who.int/iris/handle/10665/331351

  8. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the ATS and IDSA. Am J Respir Crit Care Med. 2019;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST.

  9. National Institutes of Health. NIH covid-19 treatment guidelines. Clinical spectrum of SARS-CoV-2 Infection. 2020. Available in: https://www.covid19treatmentguidelines.nih.gov/

  10. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141-154. Available in: https://doi.org/10.1038/s41579-020-00459-7

  11. Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care. 2020;24:516. doi: 10.1186/s13054-020-03240-7.

  12. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. ARDS definition task force. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307:2526-2533.

  13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort stud. Lancet. 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3.

  14. Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(6):998-1000.

  15. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4):844-847. doi: 10.1111/jth.14768.

  16. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavir|us in Wuhan, China. Lancet. 2020;395(10223):497-506.

  17. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. doi: 10.1001/jama.2020.1585.

  18. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. doi: 10.1056/NEJMoa2002032.

  19. Xie J, Covassin N, Fan Z, Singh P, Gao W, Li G, et al. Association between hypoxemia and mortality in patients with COVID-19. Mayo Clin Proc. 2020;95(6):1138-1147. doi: 10.1016/j. mayocp.2020.04.006.

  20. Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. J Thromb Haemost. 2020;120(5):876-878. doi: 10.1055/s-0040-1709650.

  21. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020;58(7):1131-1134. doi: 10.1515/cclm-2020-0198.

  22. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-768. doi: 10.1093/cid/ciaa248.

  23. Ji D, Zhang D, Chen Z, Xu Z, Zhao P, Zhang M, et al. Clinical characteristics predicting progression of COVID-19. Lancet. 2020 doi: 10.2139/ssrn.3539674.

  24. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al. The potential role of IL-6 in monitoring severe case of coronavirus disease. 2019. [Accessed on May 24, 2020] Available in: https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2




2020     |     www.medigraphic.com